The EU pays more than 1 billion euros for Remdesivir October 13, 2020September 21, 2022 Coronaheadsup.com Coronavirus, Europe, Health, Remdesivir, Treatment The European Union has agreed to pay more than 1 billion euros to Gilead for a six-month supply of its antiviral drug remdesivir, shortly before the publication of final results of the biggest trial of the COVID-19 medication. Reuters report ** This post was originally published on October 13, 2020 **Share this:Post Related Posts: Study: Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccinePreprint: Mutated SARS-CoV-2 variant resistant to remdesivirUSA: Six African lions, a Sumatran tiger and two Amur tigers infected with Covid in Washington ZooPfizer: Paxlovid not effective in reducing symptoms in standard risk patientsLong Covid: Petition calls on Germany to expedite BC007 clinical trialsLong COVID: Two more patients treated with experimental drug BC 007 see improvements in symptoms
